Multiple sclerosis (MS) — walking impairment
- Dalfampridine can improve walking speed in selected patients
- Benefit is symptomatic—not disease-modifying
- Avoid with seizure history or significant renal impairment
- Physical therapy/assistive devices remain important
- Stop if no meaningful functional benefit
- Treat spasticity/fatigue contributors separately
Use at a glance
- Dalfampridine can improve walking speed in selected patients
Practical pearls
- Benefit is symptomatic—not disease-modifying
Treatment options
- Physical therapy/assistive devices remain important
- Treat spasticity/fatigue contributors separately
Safety / pitfalls
- Avoid with seizure history or significant renal impairment
- Stop if no meaningful functional benefit
Self-check
- Is dalfampridine’s benefit for MS walking impairment disease-modifying?
No—symptomatic. - What contraindication/risk contexts require avoiding dalfampridine?
Seizure history or significant renal impairment.
Drugs used for this (1)
All clinical uses · Open Multiple sclerosis (MS) — walking impairment in the interactive console ↗